See article, p. 657.
Oncogenic V600 mutations in BRAF are found in a variety of cancers, and BRAF inhibitors such as vemurafenib have achieved clinical success in the treatment of BRAFV600-mutant melanoma. However, the clinical results of RAF inhibitors in colorectal cancer have been disappointing, prompting questions about the general efficacy of RAF inhibition across RAF-mutant cancers. Subbiah and colleagues evaluated the efficacy of vemurafenib in a phase II basket trial including 172 patients with 26 types of non-melanoma cancer. Vemurafenib was generally well tolerated, with the most common treatment-emergent adverse events being arthralgia, fatigue, and hyperkeratosis, and no deaths were deemed to have been treatment related. The overall response rate including all 26 cancers was 33%, with 3% of patients attaining complete responses and 30% attaining partial responses, and the median duration of response was 13.1 months. Responses occurred in patients with 13 of the...